Table 4 KEGG pathway enrichment analysis

hsa05219

Bladder cancer

6.34E-25

1.29E-22

3.74E-23

16

hsa05212

Pancreatic cancer

1.06E-21

1.07E-19

3.10E-20

17

hsa05161

Hepatitis B

1.58E-21

1.07E-19

3.10E-20

21

hsa05215

Prostate cancer

2.22E-21

1.13E-19

3.27E-20

18

hsa05417

Lipid and atherosclerosis

2.84E-20

1.16E-18

3.34E-19

22

hsa05167

Kaposi sarcoma-associated herpesvirus infection

7.56E-20

2.57E-18

7.42E-19

21

hsa01522

Endocrine resistance

1.14E-19

3.32E-18

9.58E-19

17

hsa05210

Colorectal cancer

4.74E-19

1.21E-17

3.49E-18

16

hsa05160

Hepatitis C

7.11E-19

1.61E-17

4.66E-18

19

hsa01524

Platinum drug resistance

1.38E-18

2.82E-17

8.14E-18

15

hsa05163

Human cytomegalovirus infection

1.73E-18

3.21E-17

9.27E-18

21

hsa05418

Fluid shear stress and atherosclerosis

1.99E-18

3.39E-17

9.80E-18

18

hsa05205

Proteoglycans in cancer

5.58E-18

8.75E-17

2.53E-17

20

hsa04933

AGE-RAGE signaling pathway in diabetic complications

6.14E-18

8.95E-17

2.59E-17

16

hsa05207

Chemical carcinogenesis—receptor activation

1.09E-17

1.48E-16

4.29E-17

20

hsa04210

Apoptosis

3.80E-17

4.85E-16

1.40E-16

17

hsa04657

IL-17 signaling pathway

7.92E-17

9.51E-16

2.75E-16

15

hsa05222

Small cell lung cancer

1.92E-15

2.18E-14

6.30E-15

14

hsa05223

Non-small cell lung cancer

2.09E-15

2.24E-14

6.47E-15

13

hsa05224

Breast cancer

3.50E-15

3.57E-14

1.03E-14

16